AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scherman, M. S.
Right arrow Articles by McNeil, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scherman, M. S.
Right arrow Articles by McNeil, M. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2003, p. 378-382, Vol. 47, No. 1
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.1.378-382.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Drug Targeting Mycobacterium tuberculosis Cell Wall Synthesis: Development of a Microtiter Plate-Based Screen for UDP-Galactopyranose Mutase and Identification of an Inhibitor from a Uridine-Based Library

Michael S. Scherman,1 Katharine A. Winans,2,1 Richard J. Stern,1,2 Victoria Jones,1 Carolyn R. Bertozzi,2 and Michael R. McNeil1*

Department of Microbiology, Colorado State University, Fort Collins, Colorado 80523,1 Departments of Chemistry and Molecular and Cell Biology and Howard Hughes Medical Institute, University of California, Berkeley, California 947202

Received 29 May 2002/ Returned for modification 19 August 2002/ Accepted 17 October 2002


   ABSTRACT
Top
 Abstract
Text
 References
 
A microtiter plate assay for UDP-galactopyranose mutase, an essential cell wall biosynthetic enzyme of Mycobacterium tuberculosis, was developed. The assay is based on the release of tritiated formaldehyde from UDP-galactofuranose but not UDP-galactopyranose by periodate and was used to identify a uridine-based enzyme inhibitor from a chemical library.


   TEXT
Top
 Abstract
 Text
References
 
The enzyme UDP-galactopyranose mutase (Glf), which catalyzes the formation of UDP-galactofuranose (UDP-galf) from UDP-galactopyranose (UDP-galp), plays a key role in the biosynthesis of the galactofuran component of the cell wall of Mycobacterium tuberculosis, as shown in Fig. 1. Many attributes of Glf suggest it as a drug target. Glf has been shown to be essential for mycobacterial growth (5). No analogous enzymatic reaction takes place in humans. UDP-galactopyranose mutase from Escherichia coli has been crystallized, its structure has been determined (3, 6), and the structure of the protein from M. tuberculosis has been just been determined to 2.5Å (Jim Naismith, personal communication). However, a convenient assay appropriate for inhibitor searches has been lacking.



View larger version (35K):
[in this window]
[in a new window]
  		FIG. 1. (A) Conversion of UDP-galactopyranose to UDP-galactofuranose as catalyzed by UDP-galactopyranose mutase (Glf, Rv3809c). (B) Structure of M. tuberculosis arabinogalactan demonstrating the key structural role of galactofuranosyl residues.

 
Previously, Glf has been assayed via high-performance liquid chromatographic separation of UDP-galf and UDP-galp (1). In an earlier attempt to provide a simpler assay, UDP-galf was used as the substrate (in the reverse direction) and the UDP-galp product was converted with two helper enzymes to UDP-glucuronic acid with concomitant reduction of NAD to NADH. However, this assay is not suitable for screening for inhibitors of the enzyme because of the difficulty of obtaining large amounts of UDP-galf, concerns about looking for inhibitors when running the reaction in the reverse direction, and the drawback that helper enzymes are required. Thus, we designed a microtiter plate-based assay to screen for potential inhibitors of this enzyme.

The M. tuberculosis Glf enzyme was expressed in E. coli (8). Purification of Glf from the E. coli extract resulted in an enzyme preparation that was less reliable in activity; this is believed to be due to irreversible loss of the flavin adenine dinucleotide cofactor (4). The E. coli strain (BL21) used to express M. tuberculosis Glf is a galE mutant and also does not have the E. coli glf gene found in E. coli K-12 (2, 7). Consequently, E. coli proteins do not act on the UDP-Galp substrate. In the assay described below, the amount of enzyme was adjusted so that about 5% of the UDP-galp present was converted to UDP-galf. This was a compromise in that enough radioactivity was produced for reproducibility but equilibrium had not been reached at 7% UDP-Galf (4).

The theory behind the new assay for Glf is presented in Fig. 2. Thus, tritiated formaldehyde is released from the product (UDP-[6-3H]Galf) but not the substrate (UDP-[6-3H]Galp) after treatment with periodate. Therefore, to assay the uridine-based library (9), 23 µl of a cocktail consisting of 25 mM HEPES (pH 7.2), 25 nmol of MgCl2, 25 nmol of freshly prepared NADH, and 2.5 nmol (~0.08 µCi) of UDP-[6-3H]galactopyranose (American Radiolabeled Chemical, St. Louis, Mo.) was added to each well of a microtiter plate. Each of the ~1,300 potential inhibitors (final concentration, 20 µM) was added in 2 µl of dimethyl sulfoxide to a single well (2 µl of dimethyl sulfoxide was added to control wells also). The reaction was started with the addition of 2 µl (500 ng) of a crude M. tuberculosis Glf enzyme preparation (8) (diluted 12-fold to a concentration of 500 ng/2 µl beforehand in a 25 mM solution of HEPES [pH 7.2] containing 10 mM NADH to reduce the flavin adenine dinucleotide coenzyme). The reaction mixtures were incubated at room temperature for 20 min; this was followed by the addition of 5 µl of 250 mM sodium acetate (pH 4.4) containing 200 mM sodium meta-periodate (NaIO4) to each well and a 15-min incubation in the dark at room temperature. The NaIO4 was then neutralized by the addition of 3 µl of ethylene glycol (undiluted) and 5 min of incubation at room temperature. After the addition of 100 µl of water to each well, the periodate-treated mixture was transferred to a 300-µl column of MTO-Dowex 1 x 8 (200 to 400 mesh) in the acetate form (Supelco, Bellefonte, Pa.) in 96 wells (7 mm [inside diameter] by 3 cm [height]) with a filter (Empore; 3M, St. Paul, Minn.). The samples were processed through the Dowex column by using a vacuum, and the columns were washed with an additional 100 µl of water. One-third of each processed sample (60 µl) was transferred to a 96-well scintillation plate (Perkin-Elmer Life Sciences, Boston, Mass.); this was followed by the addition of 180 µl of Optiphase Supermix (Perkin-Elmer Life Sciences) scintillation fluid and counting on a Perkin-Elmer Life Sciences Microbeta Trilux scintillation system.



View larger version (15K):
[in this window]
[in a new window]
  		FIG. 2. Assay for UDP-galactopyranose mutase. UDP-galf, but not UDP-galp, forms neutral tritiated formaldehyde when treated with sodium periodate.

 
A single active component, 320KAW73 (Fig. 3), was detected in the library. The component was resynthesized and purified and shown to have a 50% inhibitory concentration of approximately 6 µM (Fig. 3). The starting materials of the synthesis were also assayed for activity; the aldehyde (compound C in Fig. 3) showed a small amount of activity at 100 µM but no significant activity at lower concentrations. Other, similar compounds in the library that did not show detectable activity are shown in Fig. 4.



View larger version (34K):
[in this window]
[in a new window]
  		FIG. 3. Activity of 320KAW73 (A) and its precursors (B and C). The data shown are averages of values.

 


View larger version (16K):
[in this window]
[in a new window]
  		FIG. 4. Comparison of 320KAW73 with related compounds in the screening library that were inactive.

 
Development of a microtiter-based assay for Glf required overcoming the major hurdle of a convenient method by which to detect the product UDP-galf in a fashion consistent with microtiter plate techniques. The recognition that C-6 and its attendant hydrogens are released from UDP-galf but not from UDP-galp with periodate treatment, along with the commercial availability of UDP-[6-3H]galactopyranose, led to the solution of this problem (Fig. 2). A second problem, only partially overcome, is that the equilibrium value of the reaction lies strongly on the side of the substrate, such that only about 7% UDP-galf is present at equilibrium (4, 8). Thus, ideally, the assay should be done in the linear range of UDP-galf production, perhaps up to about 1% conversion, but this is not practical because of the amounts of radioactivity needed and the fact that a certain background production of neutral radioactivity (corresponding to ~1% conversion to UDP-Galf) occurs in the absence of enzyme. Hence, the compromise value of 4 to 6% conversion results in an assay less sensitive to inhibitors and more sensitive to random noise than ideal. We routinely include UDP at 0.1 to 1 mM as a positive control, as under the assay conditions used, UDP inhibits Glf by about 50% at 200 µM. In continuing to screen additional libraries, we did obtain false-positive assay results but these were readily identified by retesting.

Beyond the development of an assay for UDP-galactopyranose mutase, a uridine analog inhibitor of the enzyme has been uncovered. It structure is rather similar to some in the library that were inactive (Fig. 4). Of special note is the fact that the phenylsulfonyl diphosphate analog was needed as the two other spacers designed to mimic diphosphate were inactive even with the same ortho-hydroxyl di-meta nitro substituents (Fig. 4). Unfortunately, this inhibitor was not active against whole M. tuberculosis, presumably because of entry problems. However, the inhibitor may be very valuable for forming cocrystals with the enzyme. Further screening with a commercial library of drug-like compounds (obtained from Nanosyn, Menlo Park, Calif.) is in progress.


   ACKNOWLEDGMENTS
 
We gratefully acknowledge National Institutes of Health research grant AI 33706 and U19 AI 40972 (Colorado State University) and National Institutes of Health grant AI51622 (University of California) for support of this work.

We also appreciate the technical assistance of Angela Peter, Amber Stafford, Ashley Lock, Rick Jewell, and Chuck Piechota.


   FOOTNOTES
 
* Corresponding author. Mailing address: Department of Microbiology, Colorado State University, Fort Collins, CO 80523. Phone: (970) 491-1784. Fax: (970) 491-1815. E-mail: MMcneil{at}colostate.edu. Back

{dagger} Present address: Department of Medicine, Division of Infectious Diseases, Stanford University School of Medicine, Stanford, CA 94305. Back

{ddagger} Present address: Heska Corporation, Fort Collins, CO 80525. Back


   REFERENCES
Top
 Abstract
 Text
 References
 

  1. Lee, R., D. Monsey, A. Weston, K. Duncan, C. Rithner, and M. McNeil. 1996. Enzymatic synthesis of UDP-Galactofuranose and assays for UDP-galactopyranosyl mutase based on HPLC and on linked enzymatic production of NADH. Anal. Biochem. 242:1-7.[CrossRef][Medline]
  2. Liu, D., and P. R. Reeves. 1994. Escherichia coli K12 regains its O antigen. Microbiology 140:49-57.[Abstract]
  3. McMahon, S. A., G. A. Leonard, L. V. Buchanan, M. F. Giraud, and J. H. Naismith. 1999. Initiating a crystallographic study of UDP-galactopyranose mutase from Escherichia coli. Acta Crystallogr. D. Biol. Crystallogr. 55(Pt. 2):399-402.[CrossRef][Medline]
  4. Nassau, P. M., S. L. Martin, R. E. Brown, A. Weston, D. Monsey, M. McNeil, and K. Duncan. 1996. Galactofuranose biosynthesis in Escherichia coli K12: identification and cloning of UDP-galactopyranose mutase. J. Bacteriol. 178:1047-1052.[Abstract/Free Full Text]
  5. Pan, F., M. Jackson, Y. Ma, and M. R. McNeil. 2001. Determination that cell wall galactofuran synthesis is essential for growth of mycobacteria. J. Bacteriol. 183:3991-3998.[Abstract/Free Full Text]
  6. Sanders, D. R., A. G. Steins, S. A. McMahon, M. R. McNeil, C. Whitfield, and J. H. Naismith. 2001. UDP-galactopyranose mutase has a novel structure and mechanism. Nat. Struct. Biol. 8:858-863.[CrossRef][Medline]
  7. Stevenson, G., B. Neal, D. Liu, M. Hobbs, N. H. Packer, M. Batley, J. W. Redmond, L. Lindquist, and P. R. Reeves. 1994. Structure of the O antigen of Escherichia coli K-12 and the sequence of its rfb gene cluster. J. Bacteriol. 176:4144-4156.[Abstract/Free Full Text]
  8. Weston, A., R. J. Stern, R. E. Lee, P. M. Nassau, D. Monsey, S. L. Martin, M. S. Scherman, G. S. Besra, K. Duncan, and M. R. McNeil. 1998. Biosynthetic origin of mycobacterial cell wall galactofuranosyl residues. Tuber. Lung Dis. 78:123-131.
  9. Winans, K. A., and C. R. Bertozzi. 2002. An inhibitor of the human UDP-GlcNAc 4-epimerase identified from a uridine-based library: a strategy to inhibit O-linked glycosylation. Chem. Biol. 9:113-129.[CrossRef][Medline]

Antimicrobial Agents and Chemotherapy, January 2003, p. 378-382, Vol. 47, No. 1
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.1.378-382.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scherman, M. S.
Right arrow Articles by McNeil, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scherman, M. S.
Right arrow Articles by McNeil, M. R.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS